| abstract |
The invention provides a new class of deoxynojirimycin analogues, or pharmaceutically acceptable salts thereof which can suitably be used for the treatment of a disease selected from the group consisting of insulin resistance, Gauger disease, inflammatory diseases, hyperpigmentation and/or inflammatory skin conditions, overweight and obesity, lysosomal storage disorders, fungal diseases, melanoma and other tumors, and microbacterial infections. The invention further provides a pharmaceutical composition comprising said deoxynojirimycon analogue, or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. |